The 7 Wall Street analysts covering Veradermics, Inc. hold a median 12-month price target of $171 — +23.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 24 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Veradermics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (56): Analysts have, on balance, been raising their forecasts.
Volatility (3): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MANE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +23.2% from it.
Of the 19 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Oct 2026 | B. Riley Securities | Maintains | Buy | $170 → $204 |
| 19 Oct 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 19 Oct 2026 | Needham | Maintains | Buy | $164 → $172 |
| 16 July 2026 | Citigroup | Maintains | Buy | — |
| 16 July 2026 | Citigroup | Maintains | Buy | $135 → $160 |
| 15 July 2026 | B. Riley Securities | Initiates | Buy | $170 |
| 15 July 2026 | B. Riley Securities | Initiates | Buy | — |
| 15 July 2026 | Needham | Maintains | Buy | $136 → $164 |
| 15 July 2026 | Needham | Maintains | Buy | — |
| 7 July 2026 | Jefferies | Maintains | Buy | — |
| 7 July 2026 | Jefferies | Maintains | Buy | $138 → $182 |
| 16 June 2026 | LifeSci Capital | Initiates | Outperform | — |
| 2 June 2026 | Needham | Initiates | Buy | — |
| 18 May 2026 | Citigroup | Maintains | Buy | — |
| 22 Apr 2026 | Leerink Partners | Maintains | Outperform | — |
| 2 Mar 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 2 Mar 2026 | Citigroup | Initiates | Buy | — |
| 2 Mar 2026 | Jefferies | Initiates | Buy | — |
| 2 Mar 2026 | Leerink Partners | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MANE appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 13% of US stocks
Cheaper than 96% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 94% of US stocks
Higher than 7% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Veradermics, Inc. has a market value of $5.8B and an enterprise value of $5.0B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$92.7M.
Free cash flow in the twelve months to 30 June 2026: −$78.3M.
Trailing P/E: −58.5×; forward P/E: −52.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Veradermics, Inc. employs 37 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Veradermics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript in which Veradermics discussed positive top-line results from Phase III Study 304 of VDPHL01 in male pattern hair loss.
Why it matters — The transcript concerns reported clinical-trial results for a Veradermics treatment candidate.
Veradermics reported positive top-line results from Part A of Study 304, its second Phase III trial of VDPHL01, an extended-release oral minoxidil tablet being developed for men with mild to moderate pattern hair loss. The headline says the trial met all endpoints and posted strong growth results.
Why it matters — The results provide a clinical-trial update on MANE’s VDPHL01 program for male pattern hair loss.
Veradermics was listed among stocks moving higher on Monday, while U.S. stocks were mixed and the Dow Jones index fell around 100 points.
Why it matters — The item notes a Monday gain for Veradermics, relevant to MANE watchers tracking its stock movement.
Veradermics said its oral pill increased hair growth in men with pattern hair loss in a late-stage study.
Why it matters — The study result provides MANE watchers with an update on the company's oral hair-loss drug.
Veradermics announced positive topline results from Part A of Study ‘304, a registration-directed Phase 3 trial of its extended-release oral minoxidil formulation VDPHL01 in more than 500 males with mild-to-moderate pattern hair loss. The company described the hair-growth results as early, consistent, and robust.
Why it matters — The results provide a positive clinical update on MANE’s lead hair-loss treatment candidate in a Phase 3 trial.
The 7 Wall Street analysts covering Veradermics, Inc. have a median 12-month price target of $171, with estimates ranging from $135 to $204. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Veradermics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Veradermics, Inc. 3 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Oct 2026, Veradermics, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (56 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +23.2% from the last close, and Ticker Nerd's factor model ranks Veradermics, Inc. 3 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Veradermics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MANE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $135 to $204 over the next 12 months.
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company focused on developing dermatology and aesthetic treatments. Its current pipeline centers on therapies for pattern hair loss, including VDPHL01, an oral, non-hormonal, extended-release minoxidil formulation designed for men and women.
The most recent item we track (Seeking Alpha, 19 Oct 2026): "Veradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair Loss Transcript". Seeking Alpha published a transcript in which Veradermics discussed positive top-line results from Phase III Study 304 of VDPHL01 in male pattern hair loss.
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company focused on developing dermatology and aesthetic treatments. Its current pipeline centers on therapies for pattern hair loss, including VDPHL01, an oral, non-hormonal, extended-release minoxidil formulation designed for men and women. The company is also developing additional product candidates and delivery technologies for common skin and hair-related conditions such as alopecia areata, common warts, molluscum contagiosum, and atopic dermatitis. Veradermics serves healthcare providers, dermatology clinicians, and medical researchers involved in treating adult and pediatric patients. Headquartered in New Haven, Connecticut, and incorporated in 2019, Veradermics operates as a focused biotech company addressing prevalent dermatologic conditions through targeted therapeutic development.
CEO Dr. Reid Waldman M.D. · 37 employees · United States · https://www.veradermics.com
